Skip to main content

Table 2 Previously used preventive medication before starting a monoclonal antibody including the reason for discontinuing the treatment

From: Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series

 

Non-Responder

Side Effects

Loss-of-Efficacy

Other

Total

Beta-Blocker

48 (57.1)

18 (21.4)

7 (8.3)

11 (13.1)

84 (49.1)

Topiramate

35 (41.7)

36 (42.9)

5 (6.0)

8 (9.5)

84 (49.1)

Flunarizine

29 (46.8)

21 (33.9)

3 (4.8)

9 (14.5)

62 (36.3)

Amitriptyline

38 (59.4)

15 (23.4)

1 (1.6)

10 (15.6)

64 (37.4)

OnabotulinumtoxinA

17 (85.0)

1 (5.0)

-

2 (10.0)

20 (11.7)

Valproic acid

10 (55.6)

5 (27.8)

2 (11.1)

1 (5.6)

18 (10.5)

Candesartan

5 (62.5)

-

-

3 (37.5)

8 (4.7)

Venlafaxine

4 (57.1)

0 (0.0)

-

3 (42.9)

7 (4.1)

Tanacetum parthenium

6 (85.7)

-

-

1 (14.3)

7 (4.1)

Other

23 (65.7)

4 (11.4)

-

8 (22.9)

35 (20.5)

  1. Values are absolute numbers and percent (%)